Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.77), $0.27 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $34.14 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.